AHA GUIDELINES Bundle (free trial)

Disclaimer is resource is for informational purposes only, intended as a quick-reference tool based on the cited source guideline(s), and should not be used as a substitute for the independent professional judgment of healthcare providers. Practice guidelines are unable to account for every individual variation among patients or take the place of clinician judgment, and the ultimate decision concerning the propriety of any course of conduct must be made by healthcare providers aer consideration of each individual patient situation. Guideline Central does not endorse any specific guideline(s) or guideline recommendations and has not independently verified the accuracy hereof. Any use of this resource or any other Guideline Central resources is strictly voluntary. Source Blumenthal, RS, Morris, PB, Gaudino, M, Johnson, HM, Anderson, TS, Bittner, VA, Blankstein, R, Brewer, LC, Cho, L, de Ferranti, SD, Gianos, E, Gluckman, TJ, Gradney, K, Isiadinso, I, Lloyd-Jones, DM, Marrs, JC, Martin, SS, McLain, KH, Mehta, LS, Mora, S, Mulugeta, WM, Natarajan, P, Navar, AM, Orringer, CE, Polonsky, TS, Reynolds, HR, Saseen, JJ, Shapiro, MD, Soffer, DE, Tynes, SA, Villavaso, CD, Virani, SS, Wilkins, JT. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/ APhA/ASPC/NLA/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiolog y/American Heart Association Joint Committee on Clinical Practice Guidelines. [published online ahead of print March 13, 2026]. J Am Coll Cardiol. doi: 10.1016/j.jacc.2025.11.016. Copublished in Circulation. doi: 10.1161/CIR.0000000000001423. ACCDYS03263c TEL: 407.878.7606 Order additional copies at GuidelineCentral.com Copyright © 2026 All rights reserved GuidelineCentral.com Abbreviations ABI, ankle-brachial index; ACS, acute coronary syndrome; aHR, adjusted hazard ratio; AOR, adjusted odds ratio; ApoB, apolipoprotein B; ARR, absolute risk reduction; ASCVD, atherosclerotic cardiovascular disease; ATP, adenosine triphosphate; AU, Agatston units; AUC, area under the curve; BMI, body mass index; CAC, coronary artery calcium; CAD, coronary artery disease ; CHD, coronary heart disease; CI, confidence interval ; CID, chronic inflammatory diseases; CK, creatine kinase; CKD, chronic kidney disease; CKM, cardiovascular-kidney-metabolic; CT, computed tomography; CTA, computed tomography angiography; CCTA, coronary computed tomography angiography; CVD, cardiovascular disease; CVOT, cardiovascular outcome trial; CYP3A4, cytochrome P450 3A4; DASH, Dietary Approach to Stop Hypertension; DDI, drug-drug interactions; DHA, docosahexanoic acid; eGFR, estimated glomerular filtration rate; EPA, eicosapentanoic acid; FCS, familial chylomicronemia syndrome; FDA, US Food and Drug Administration; FH, familial hypercholesterolemia; HDL-C, high- density lipoprotein-cholesterol; HeFH, heterozygous familial hypercholesterolemia; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; HIV, human immunodeficiency virus; HMG-CoA, 3-hydroxy-3-methylglutaryl- coenzyme; HoFH, homozygous familial hypercholesterolemia; HR, hazard ratio; HsCRP, high-sensitivity C-reactive protein; IPE, icosapent ethyl; LDL, low-density lipoprotein; LDL-C, low-density lipoprotein-cholesterol; LLT, lipid-lowering therapy; Lp(a), lipoprotein (a); LPL, lipoprotein lipase; mAbs, monoclonal antibodies; MACE, major adverse cardiovascular events; MASLD, metabolic dysfunction-associated steatotic liver disease; MCS, multifactorial chylomicronemia syndrome; MI, myocardial infarction; NIH, National Institutes of Health; PAD, peripheral artery disease; PCSK9i, proprotein convertase subtilisin/kexin type 9 inhibitor; PLHIV, persons living with HIV; PREVENT, Predicting Risk of cardiovascular disease EVENTs; PRS, polygenic risk scoring ; QOL, quality of life; RCT, randomized controlled trial; RDN, registered dietitian nutritionist; RNA, ribonucleic acid; RRR, relative risk reduction; SAMS, statin-attributed muscle symptoms; TC, total cholesterol; TG, triglycerides; VLDL, very-low-density lipoprotein

• Cover